Peptidomics analysis of human blood specimens for biomarker discovery

被引：28

作者：

Tammen, Harold

Peck, Andrew

Budde, Petra

Zucht, Hans-Dieter

机构：

[1] Digilab Bio Vision GmbH, D-30625 Hannover, Germany

[2] Med Res Digilab Bio Vision GmbH, D-30625 Hannover, Germany

[3] Digilab Inc, Canton, MA 02021 USA

来源：

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2007年 / 7卷 / 05期

关键词：

biomarker; mass spectrometry; inhibition; peptide; peptidomics; protease; proteomics; validation;

D O I：

10.1586/14737159.7.5.605

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

This review addresses the concepts, limitations and perspectives for the application of peptidomics science and technologies to discover putative biomarkers in blood specimens. Peptidomics can be defined as the comprehensive multiplex analysis of endogenous peptides contained within a biological sample under defined conditions to describe the multitude of native peptides in a biological compartment. In addition to the discovery of disease associated biomarkers, an emerging field in peptidomics is the analysis of peptides to describe in vivo effects of protease inhibitors. The development and application of peptidomics technologies represent an arena of biomarker research that has the potential for adding significant clinical value.

引用

页码：605 / 613

页数：9

共 72 条

[1] The human plasma proteome - History, character, and diagnostic prospects [J].